Moderna's stock soared after the COVID-19 vaccine maker detailed progress in developing a potential preventive shot for melanoma, a deadly form of skin cancer.
vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed.
Phase 3 is generally the largest and most expensive stage of clinical research before regulators review a potential drug for approval., and the drugmaker brought in more than $3 billion from its Spikevax in this year's third quarter.Like Spikevax, the potential skin cancer vaccine uses mRNA technology. It trains a patient's immune system to recognize and respond specifically to mutations in the DNA of the patient's tumor.
The patient group that took the potential vaccine and Keytruda saw a 44% reduction in the risk of death or the cancer returning, the companies said.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Merck, Moderna detail potential skin cancer vaccine progressMerck and Moderna said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had the tumors removed in surgery.
Leer más »
Moderna and Merck team-up to fight melanomaVaccine-maker Moderna has partnered with the biopharmaceutical company Merck to create an effective treatment for skin cancer
Leer más »
Positive Moderna, Merck cancer vaccine data advances mRNA promise, shares riseAn experimental cancer vaccine from Moderna based on the messenger RNA technology used in successful COVID vaccines has been shown to work against melanoma.
Leer más »
Merck, Moderna detail potential skin cancer vaccine progressModerna’s stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer. The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed.
Leer más »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Leer más »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Leer más »